Shockwave Medical Stock
Treatment for Advanced Cardiovascular Disease
Sign up today and learn more about Shockwave Medical Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Shockwave Medical Stock
Shockwave Medical is developing the Lithoplasty™ family of balloon dilatation catheters that incorporate tiny lithotripsy electrodes designed to increase the compliance of rigid vascular and valvular lesions prior to low-pressure dilation, thereby limiting injury to healthy tissue and overcoming significant limitations of current revascularization technologies. The technology is built on traditional balloon catheter platforms rendering it inherently familiar and easy to use for cardiologists, interventional radiologists and vascular surgeons alike. In peripheral vessels, Lithoplasty™ could enable more effective angioplasty, less frequent bailout stent usage and enhanced lesion preparation prior to the use of drug eluting balloons (DEB) or bio-absorbable vascular scaffolds (BVS). In coronary vessels it could facilitate stent delivery and enhance vessel preparation prior to stent or BVS placement. Finally, in aortic valves the technology could vastly improve native tissue preparation prior to trans-catheter aortic valve replacement (TAVR) and valvuloplasty for those patients not suitable for TAVR.
Investors
T. Rowe Price
One97, Flipkart, WeWork, Cruise, Airbnb, Rivian, Magic Leap, Nuro, Caris Life Sciences, Vroom
Venrock
Devoted Health, Zenefits, TAE Technologies, Dollar Shave Club, Lucid Motors, Dataminr, 6sense, AppNexus, Salsify, Astranis
Fidelity Management and Research
MasterClass, Wheels Up, Rent the Runway, Somatus, ACV, The Honest Company, Cleerly, Oportun, 10X Genomics, MNTN
Funding History
January 2014 | $12.5M |
---|---|
May 2015 | $40.0M |
November 2016 | $45.0M |
October 2017 | $35.0M |
Management
Co-Founder
Todd Brinton
Founder, Senior Advisor
Daniel Hawkins